Trastuzumab biosimilar - NeuClone/Serum Institute of India
Alternative Names: NeuCeptinLatest Information Update: 15 Jan 2022
At a glance
- Originator NeuClone; Serum Institute of India
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Cancer; Gastric cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in Australia (IV, Infusion)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Gastric-cancer(In volunteers) in Australia (IV, Infusion)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in India (IV)